These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11126059)

  • 1. A pill turned bitter. How a quest for a blockbuster drug went fatally wrong.
    Shapiro JP
    US News World Rep; 2000 Dec; 129(23):54-6. PubMed ID: 11126059
    [No Abstract]   [Full Text] [Related]  

  • 2. Contemporary thoughts on the treatment of irritable bowel syndrome.
    Giaquinta D
    Manag Care Interface; 2002 Aug; 15(8):19-20, 22. PubMed ID: 12229060
    [No Abstract]   [Full Text] [Related]  

  • 3. Lotronex withdrawn from market.
    Harv Womens Health Watch; 2001 Feb; 8(6):6. PubMed ID: 11175468
    [No Abstract]   [Full Text] [Related]  

  • 4. Lotronex and the FDA: a fatal erosion of integrity.
    Horton R
    Lancet; 2001 May; 357(9268):1544-5. PubMed ID: 11377636
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA advisers warn of more deaths if drug is relaunched.
    Moynihan R
    BMJ; 2002 Sep; 325(7364):561. PubMed ID: 12228121
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA advisory panels recommend Lotronex be put back on market.
    Charatan F
    BMJ; 2002 May; 324(7345):1053. PubMed ID: 11993482
    [No Abstract]   [Full Text] [Related]  

  • 7. Return of alosetron.
    Hyman PE; Garvey TQ
    Expert Opin Drug Saf; 2002 May; 1(1):1-4. PubMed ID: 12904154
    [No Abstract]   [Full Text] [Related]  

  • 8. Irritable bowel syndrome. A poorly understood disorder.
    Lewis C
    FDA Consum; 2001; 35(4):30-6. PubMed ID: 11692885
    [No Abstract]   [Full Text] [Related]  

  • 9. Alosetron: a case study in regulatory capture, or a victory for patients' rights?
    Moynihan R
    BMJ; 2002 Sep; 325(7364):592-5. PubMed ID: 12228140
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA approves restricted marketing of Lotronex.
    FDA Consum; 2002; 36(4):4. PubMed ID: 12184306
    [No Abstract]   [Full Text] [Related]  

  • 12. Grappling with the quality of life. Patients, FDA and drug companies struggle to link therapies with well-being.
    Lewis C
    FDA Consum; 2001; 35(2):30-5. PubMed ID: 11444246
    [No Abstract]   [Full Text] [Related]  

  • 13. Glaxo Wellcome withdraws irritable bowel syndrome medication.
    FDA Consum; 2001; 35(1):3. PubMed ID: 11930921
    [No Abstract]   [Full Text] [Related]  

  • 14. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA draws patients into alosetron risk management.
    Miller JL
    Am J Health Syst Pharm; 2000 Oct; 57(19):1736. PubMed ID: 11030021
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug for irritable bowel syndrome taken off the market.
    Charatan F
    BMJ; 2000 Dec; 321(7274):1429. PubMed ID: 11228674
    [No Abstract]   [Full Text] [Related]  

  • 17. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
    Palmer RH
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.
    Avigan M; Justice R; Mackey AC; Nair N
    Am J Gastroenterol; 2003 Sep; 98(9):2105-6. PubMed ID: 14499800
    [No Abstract]   [Full Text] [Related]  

  • 19. Alosetron to return to market.
    Young D
    Am J Health Syst Pharm; 2002 Jul; 59(14):1323-4. PubMed ID: 12132555
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA allows controversial bowel drug back on to market.
    McCarthy M
    Lancet; 2002 Jun; 359(9323):2095. PubMed ID: 12086774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.